April 12, 2012 / 12:52 PM / 6 years ago

Abiomed's heart pump gets EU nod

(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003. REUTERS/Fabrizio Bensch

The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.

The device is intended for use in cardiac surgery for supporting the weakened heart’s left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.

Impella cVAD is still not approved in the United States.

Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.

Reporting by Anand Basu in Bangalore; Editing by Viraj Nair

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below